Search Results
Results found for "Ben Jones"
- Murat Tunaboylu & Ben Holland | Dr. GPCR Ecosystem
<< Back to podcast list Strategic Partner(s) Murat Tunaboylu & Ben Holland About Murat Tunaboylu "Murat GPCR About Ben Holland "Ben gained his masters in Engineering Science from Oxford, taking a specialisation nearly 10 years, applying it to antibody generation, analysis, and property prediction since 2017" Ben
- When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements | Dr. GPCR Ecosystem
GPCR scientist Ben Clements shares how positive allosteric modulators could transform opioid therapy From Aspirations to Application: Benâs Path into Science Ben shares his winding yet deliberate entry Allosteric Modulation: The New Frontier of GPCR Drug Discovery Ben reflects on the emerging potential We produce great data, but we also joke around. Thatâs how we work best.â About Ben Clements Dr.
- Dr. Benjamin Myers | Dr. GPCR Ecosystem
Benjamin Myers Ben Myers is an assistant professor at the University of Utah School of Medicine in Salt Benâs research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic More recently, Benâs lab has begun studying GPCR signaling pathways that operate within the primary cilium Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure
- Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap | Dr. GPCR Ecosystem
Her lab studies chemokine receptor CCR1 in multiple myeloma and cancer-to-bone metastasis, free fatty An inverse agonist where none had been reported - constitutive beta-arrestin coupling at FFA2 Gilchrist's Almost no company with an approved GPCR-targeting drug has gone back to look at what common receptor The question that followed was immediate: why hadn't anyone done the same with G-protein C-termini? single reading of someone else's work and a recognition that an obvious experiment had not yet been done
- Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering of Receptor Selectivity | Dr. GPCR Ecosystem
Receptor Selectivity The parathyroid hormone receptor sits at the intersection of calcium homeostasis, bone focus on the parathyroid hormone receptor and its downstream consequences for calcium homeostasis and bone PTH-based therapies is hypercalcemia, driven in part by receptor activity in kidney tissue rather than bone Connecting a ligand to a tissue-targeted nanobody could restrict receptor activation to bone and reduce protease stability, and receptor conformation selectivity 21:40 PTH receptor pharmacology: calcium spikes, bone
- Dr. Alix A. J. Rouault | Dr. GPCR Ecosystem
Coneâs lab was a clear choice for a postdoc. Dr. Cone was the first to clone the melanocortin receptors (the GPCRs that led to the discovery of MRAP2)
- Dr. Nariman Balenga | Dr. GPCR Ecosystem
parathyroid glands of patients with hyperparathyroidism and their impact on body calcium homeostasis and bone
- Paul Insel: Unbiased Discovery and the GPCRs We've Been Missing | Dr. GPCR Ecosystem
that changed the direction of a lab 47:30 The future of the GPCR superfamily and the work still to be done "Nature decided, for reasons that none of us will ever probably know for sure, that GPCRs should be the physiology, receptor molecular pharmacology in cells, and animal models, and as he puts it has now heâs "gone
- About Dr. GPCR Podcast | Dr. GPCR Ecosystem
Anita Nivedha I think it's really well done.
- Re-cap of Endocrine Metabolic GPCR 2024 with the Organizers | Dr. GPCR Ecosystem
Her current research focuses on how metabolic GPCRs cross-talk and interact to regulate appetite and bone
- Timeline Strategy | Scaling Biotech Operations with Dr. GPCR
. đ This is where str Attila Foris Feb 23 The Moment Biotech Founders Realize the Money Is Gone đ Most
- Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes | Dr. GPCR Ecosystem
to drug discovery is grounded in classical physiology and driven by a willingness to enter fields - bone professional cost that nobody warns you about Moving between neuroscience, reproductive endocrinology, bone
- From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem
entrepreneurial lessons no one tells postdocs: how to pitch, fail, and build a team Why asking âwhat if it can be done
- Brian Arey: Discovering Signaling Bias at the FSH Receptor | Dr. GPCR Ecosystem
01:55 What pharmacologists bring to drug discovery that nobody else does SELECTED QUOTES "If you've done all the controls appropriately, and you've done the experiments to the best of your ability, and you've
- Exploring Career Paths in GPCR Research with Dr. Jacek MokrosiĆski | Dr. GPCR Ecosystem
They also highlighted the need for a work-life balance and the joy of a well-done job.
- Graciela Pineyro: Resilience, Lab Life, and the Zoom Effect | Dr. GPCR Ecosystem
She has done extensive work on the molecular pharmacology of opioid receptors and is currently focusing
- Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar & Ilana Kotliar | Dr. GPCR Ecosystem
A Long-Term Vision Realized âWe've done this work for the past 30 years.â â Tom Sakmar Dr.
- Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling | Dr. GPCR Ecosystem
Not casual, not opinion-writing; dry-lab pharmacology done with the same seriousness as bench work, just
- Terry Hébert | Dr. GPCR Ecosystem
students â especially international students far from their families â connected to a lab that has gone
- Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem
Serendipity and Risk in Discovery â From the accidental observation of GPCR dimers to negative controls gone Pointed Forward The Trevena biased agonist for the AT1 receptor failed in clinical trials, meeting none
- Debbie Hay: Class B GPCRs, RAMPs, and the Migraine Pharmacology Gap | Dr. GPCR Ecosystem
receptor genes - yet they govern a disproportionately wide range of physiology, from calcitonin-mediated bone
- Graciela Piñeyro: Partial Agonism, Receptor Recycling, and the Limits of Bias | Dr. GPCR Ecosystem
conformations â how the same ligand can behave as agonist or inverse agonist depending on receptor tone Graciela has done extensive work on the molecular pharmacology of opioid receptors, exploring their signaling
- Pod-Be Our Guest - Public | Dr. GPCR Ecosystem
Recordings are done on Zoom. Touch-up- my appearance. Adjust for low light.
- Antony Boucard: Adhesion GPCRs and the Molecular Code of Synapse Formation | Dr. GPCR Ecosystem
spider toxin binding site â on adhesion GPCRs, synapse formation, and building a research program where none biochemistry, cell biology, and translational thinking could do something that wasn't already being done






















